Literature DB >> 17909081

Immunogenicity of umbilical cord tissue derived cells.

Patricia S Cho1, Darin J Messina, Erica L Hirsh, Nina Chi, Stephanie N Goldman, Diana P Lo, Ian R Harris, Sicco H Popma, David H Sachs, Christene A Huang.   

Abstract

Umbilical cord tissue provides a unique source of cells with potential for tissue repair. Umbilical cord tissue-derived cells (UTCs) are MHC class I (MHCI) dull and negative for MHC class II (MHCII), but can be activated to increase MHCI and to express MHCII with IFN-gamma stimulation. Mesenchymal stem cells with similar characteristics have been inferred to be nonimmunogenic; however, in most cases, immunogenicity was not directly assessed. Using UTC from Massachusetts General Hospital MHC-defined miniature swine, we assessed immunogenicity across a full MHC barrier. Immunogenicity was assessed by in vitro assays including mixed lymphocyte reaction (MLR) and flow cytometry to detect serum alloantibody. A single injection of MHC-mismatched unactivated UTCs did not induce a detectable immune response. When injected in an inflamed region, injected repeatedly in the same region or stimulated with IFN-gamma prior to injection, UTCs were immunogenic. As clinical cellular repair strategies may involve injection of allogeneic cells into inflamed regions of damaged tissue or repeated doses of cells to achieve the desired benefit, our results on the immunogenicity of these cells in these circumstances may have important implications for optimal success and functional improvement for this cellular treatment strategy for diseased tissues.

Entities:  

Mesh:

Year:  2007        PMID: 17909081     DOI: 10.1182/blood-2007-03-078774

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  77 in total

1.  Cytotherapy with naive rat umbilical cord matrix stem cells significantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice.

Authors:  Chiyo Doi; Dharmendra Kumar Maurya; Marla M Pyle; Deryl Troyer; Masaaki Tamura
Journal:  Cytotherapy       Date:  2010-05       Impact factor: 5.414

Review 2.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

3.  Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells.

Authors:  Limin Wang; Mark L Weiss; Michael S Detamore
Journal:  Recent Pat Regen Med       Date:  2013

Review 4.  Immunomodulation by mesenchymal stem cells in veterinary species.

Authors:  Danielle D Carrade; Dori L Borjesson
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

Review 5.  Cord blood--an alternative source for bone regeneration.

Authors:  Marcus Jäger; Christoph Zilkens; Bernd Bittersohl; Rüdiger Krauspe
Journal:  Stem Cell Rev Rep       Date:  2009-08-04       Impact factor: 5.739

6.  Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy.

Authors:  Karen Bieback; Irena Brinkmann
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

7.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

Review 8.  Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord.

Authors:  Cun-Gang Fan; Qing-jun Zhang; Jing-ru Zhou
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

9.  Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.

Authors:  S Jyothi Prasanna; Divya Gopalakrishnan; Shilpa Rani Shankar; Anoop Babu Vasandan
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

10.  Therapy with un-engineered naïve rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma.

Authors:  Dharmendra K Maurya; Chiyo Doi; Atsushi Kawabata; Marla M Pyle; Clay King; Zhihong Wu; Deryl Troyer; Masaaki Tamura
Journal:  BMC Cancer       Date:  2010-10-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.